Arrayjet, a number one supplier of inkjet liquid-handling options, right now introduced that its ArrayPlex™ discovery platform has been chosen by Immunome, Inc. (NASDAQ: IMNM), a biotechnology firm devoted to growing first-in-class and best-in-class focused most cancers therapies, to develop its in-house high-throughput screening instruments.
The proprietary multi-layer microarray platform can be obtainable to Arrayjet’s screening prospects by way of its CRO/CMO providers or by the shopper buying an instrument and performing screening in-house.
ArrayPlex was created by Arrayjet to fulfill the distinctive assay necessities of its prospects for high-throughput screening providers and instruments. Throughout Arrayjet’s profitable seven-year partnership with Immunome, Arrayjet carried out screening providers utilizing the ArrayPlex platform, and the platform underwent additional optimisation, most lately to combine inner assay controls and enhanced information normalisation.
Arrayjet is happy that Immunome has now chosen to buy an instrument and internalise the ArrayPlex assay as an in-house, high-throughput screening useful resource in its efforts to find focused most cancers therapies.
Harnessing Arrayjet’s distinctive inkjet expertise for bioprinting, ArrayPlex is a patented spot-on-spot microarray platform that permits the speedy creation of multi-layered assays. This strategy permits two libraries to be screened in opposition to one another for distinctive binding interactions, producing hits with out prior information of both ligand or goal at very high-throughput – sometimes offering two-million information factors per one 10-day cycle.
Along with screening between antibody and lysate libraries, the platform can be suitable with a broad spectrum of different pattern varieties (e.g. small molecule libraries, protein panels, nucleic acid libraries), detecting hits at an equal or increased sensitivity in comparison with ELISA.
“ArrayPlex is a significant success story for Arrayjet; a fruits of years of onerous work.”
Dr Iain McWilliam, Chief Government Officer of Arrayjet
“Over time, we’ve got screened tons of of hundreds of antibodies in opposition to tons of of most cancers tissue lysates all of the whereas honing the assay. As a staff, we’re proud to see ArrayPlex integrated into Immunome’s highly effective in-house operations as considered one of its instruments for advancing most cancers therapeutic discovery, and we’re excited concerning the platform additionally being obtainable to our wider buyer base.”
Dr Iain McWilliam, Chief Government Officer of Arrayjet
For extra info on Arrayjet’s ArrayPlex microarray platform: https://arrayjet.com/arrayplex-multilayered-microarrays
Supply hyperlink
